<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096457</url>
  </required_header>
  <id_info>
    <org_study_id>ABF-BO-2016-102</org_study_id>
    <nct_id>NCT03096457</nct_id>
  </id_info>
  <brief_title>Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia</brief_title>
  <official_title>Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Nacional de Dermatologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Nacional de Dermatologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb)
      to placebo for L braziliensis in Bolivia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized between Paromomycin cream applied topically once daily for 20
      days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days
      1, 3, 5 (group 2—20 patients), and cream vehicle applied topically once daily for 20 days
      (group 3—20 patients).

      After treatment, all patients will be followed for 1, 3, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Anticipated">October 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized between Paromomycin cream applied topically once daily for 20 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days 1, 3, 5 (group 2—20 patients), and cream vehicle applied topically once daily for 20 days (group 3—20 patients).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Group 1 (Paromomycin cream) will be compared to Group 3 (Vehicle cream). Both creams will have very similar physical characteristics and package. Group 2 (intralesional injection of pentamidine) will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Lesion size</measure>
    <time_frame>6 months</time_frame>
    <description>change of lesion area at 6 months after treatment compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treated-related adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Adverse events will measured according to CTCAE 4.03</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leishmaniasis, Cutaneous</condition>
  <condition>Leishmania Braziliensis Complex</condition>
  <condition>Leishmaniasis, American</condition>
  <condition>Leishmaniasis; American, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Group 1 - Paromomycin cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2. Local Injectable Pentamidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.
A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3. Vehicle control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin Sulfate</intervention_name>
    <description>topical application 2 times a day during 20 days</description>
    <arm_group_label>Group 1 - Paromomycin cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine Isethionate</intervention_name>
    <description>3 Intralesional injections at days 1,3 and 5</description>
    <arm_group_label>Group 2. Local Injectable Pentamidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical application 2 times a day during 20 days</description>
    <arm_group_label>Group 3. Vehicle control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Male or female

          -  Age: &gt;12 yrs of age

          -  Presentation: 1-to-2 ulcerative lesions, each &lt; 30 mm in largest diameter and with a
             total lesion area &lt;900 mm2.

          -  Parasitology: Parasitological confirmation of the lesion will be made by visualization
             or culture of Leishmania from the biopsy or aspirate of the lesion.

        Exclusion Criteria:

          -  Previous treatment for leishmaniasis with Sb, pentamidine, amphotericin B,
             miltefosine, imidazoles, allopurinol in the last 3 months.

          -  Other diseases that would be likely in the PI's opinion to interact, either positively
             or negatively, with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JAIME SOTO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Nacional de Dermatologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JAIME SOTO, MD</last_name>
    <phone>59133515152</phone>
    <email>jaime.soto@dermalaserbolivia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Local Palos Blancos</name>
      <address>
        <city>Palos Blancos</city>
        <state>La Paz</state>
        <zip>00000</zip>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROLANDO PARRA, DO</last_name>
      <phone>72130080</phone>
      <email>rolo_parra67@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dermatologico de Jorochito</name>
      <address>
        <city>Jorochito</city>
        <state>SC</state>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Paz, MD</last_name>
      <phone>59133458001</phone>
      <email>david.paz_60@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Paz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>daniela Rivero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bolivia</country>
  </location_countries>
  <reference>
    <citation>Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil--an area of Leishmania (V.) braziliensis transmission. Int J Dermatol. 1997 Jun;36(6):463-8.</citation>
    <PMID>9248897</PMID>
  </reference>
  <reference>
    <citation>Vasconcellos Ede C, Pimentel MI, Schubach Ade O, de Oliveira Rde V, Azeredo-Coutinho RB, Silva Fda C, Salgueiro Mde M, Moreira JS, Madeira Mde F, Baptista C, Valete-Rosalino CM. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg. 2012 Aug;87(2):257-60.</citation>
    <PMID>22855754</PMID>
  </reference>
  <reference>
    <citation>Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, Cruz M, Gracia L, Villarroel D, Alavi I, Toledo J, Berman J. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis. 2013 May;56(9):1255-60. doi: 10.1093/cid/cit049. Epub 2013 Feb 6.</citation>
    <PMID>23390069</PMID>
  </reference>
  <reference>
    <citation>Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, Berman J. Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2016 Apr;94(4):852-6. doi: 10.4269/ajtmh.15-0640. Epub 2016 Feb 22.</citation>
    <PMID>26903605</PMID>
  </reference>
  <reference>
    <citation>Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. doi: 10.1056/NEJMoa1202657.</citation>
    <PMID>23388004</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leishmaniasis</keyword>
  <keyword>L.braziliensis</keyword>
  <keyword>paromomycin cream</keyword>
  <keyword>intralesional pentamidine</keyword>
  <keyword>leishmaniasis local therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
    <mesh_term>Leishmaniasis, Mucocutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paromomycin</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

